Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Immunology
IF: 1.404 5-Year IF: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Print: 1040-8401
ISSN Online: 2162-6472

Volumes:
Volume 40, 2020 Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v27.i5.20
pages 415-436

Targeting OX40 and OX40L for the Treatment of Autoimmunity and Cancer

William L. Redmond
Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, 4805 NE Glisan St., No. 5F37, Portland, OR 97213, USA
Andrew D. Weinberg
Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, 4805 NE Glisan St., No. 5F37, Portland, OR 97213, USA

ABSTRACT

The optimal activation of naïve T cells requires TCR−mediated recognition of cognate peptide−MHC complexes on antigen presenting cells in the presence of costimulatory signals. Although signals provided via CD28−B7 interactions are important for enhancing the initial T−cell response, other costimulatory signals are required for sustaining the response and promoting both T−cell differentiation and survival. In particular, engagement of OX40 (CD134) by its natural ligand OX40L (CD134L) or OX40 agonists has been shown to provide key signals that can augment CD4 and CD8 T−cell responses. Importantly, numerous studies have highlighted the ability of OX40−specific agonists or antagonists to enhance antitumor immunity or ameliorate autoimmune disease, respectively. On the basis of these studies, the development of OX40− and OX40L−specific reagents has been pursued for clinical use. Given the emerging role of OX40 and OX40L as novel therapeutic targets, this review will focus on the cellular and molecular mechanisms of OX40−mediated T−cell costimulation with a special emphasis on the role of OX40-OX40L interactions in the etiology and treatment of autoimmunity and cancer.


Articles with similar content:

Role of Diacylglycerol Kinases in T Cell Development and Function
Critical Reviews™ in Immunology, Vol.33, 2013, issue 2
Sruti Krishna , Xiaoping Zhong
MHC Transfer from APC to T Cells Following Antigen Recognition
Critical Reviews™ in Immunology, Vol.26, 2006, issue 1
Scott A. Wetzel, David C. Parker
Innate Recognition of Bacteria: Engagement of Multiple Receptors
Critical Reviews™ in Immunology, Vol.22, 2002, issue 4
Ulrich Seydel, Thomas Gutsmann, Klaus Brandenburg, Kathy Triantafilou, Martha Triantafilou
Costimulation Signals for Memory CD8+ T Cells During Viral Infections
Critical Reviews™ in Immunology, Vol.29, 2009, issue 6
Peter D. Katsikis, Alina C. Boesteanu, Priyanka A. Duttagupta
Naturally Occurring Regulatory T Cells: Recent Insights in Health and Disease
Critical Reviews™ in Immunology, Vol.27, 2007, issue 1
Penelope A. Morel, Giorgio Raimondi, Michael S. Turner, Angus W. Thomson